Fonte: Clinical Colorectal Cancer. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, QUIMIOTERAPIA ADJUVANTE, ANTINEOPLÁSICOS, AVANÇO DA DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTÁSIO, Bruno Mendonça et al. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, v. 16, n. 1, p. 65-72, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2016.07.001. Acesso em: 26 out. 2025.APA
Protásio, B. M., Matutino, A., Lage, L. V., Santana, I., Ramos, R., Sabbaga, J., et al. (2017). Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, 16( 1), 65-72. doi:10.1016/j.clcc.2016.07.001NLM
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2025 out. 26 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001Vancouver
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2025 out. 26 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001
